Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dystrophin (DMD) - Overview
Dystrophin (DMD) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dystrophin (DMD) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dystrophin (DMD) - Companies Involved in Therapeutics Development
Dystrophin (DMD) - Drug Profiles
Dystrophin (DMD) - Dormant Products
Dystrophin (DMD) - Discontinued Products
Dystrophin (DMD) - Product Development Milestones
Featured News & Press Releases
Apr 07, 2022: Dystrogen Therapeutics investigatiol chimeric cell therapy DT-DEC01 for the treatment of Duchene Muscular Dystrophy shows safety and functiol improvements
Apr 06, 2022: PepGen announces first participant dosed in a phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy
Mar 18, 2022: Exon 44-targeted DMD drug hits goals in PI/II: NCNP/Nippon Shinyaku
Mar 17, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
Mar 15, 2022: PepGen announces approval by Health Cada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular Dystrophy
Mar 11, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
Mar 08, 2022: Roche to present new SRP-9001 data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Jan 10, 2022: Sarepta Therapeutics’ Gene Therapy SRP-9001 shows statistically significant functiol improvements compared to pre-specified matched exterl control in Part 2 of study SRP-9001-102 for the treatment of Duchenne Muscular Dystrophy
Jan 07, 2022: FDA grants IND clearance for REGENXBIO’s gene therapy trial for Duchenne
Jan 06, 2022: Sarepta Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
Nov 29, 2021: Nippon Shinyaku implements VILTEPSO maged access program
Nov 25, 2021: Addition of Viltepso to the list of Injection Drugs that physicians providing health insurance treatment can administer
Nov 22, 2021: REGENXBIO announces Orphan Drug Desigtion granted to RGX-202, a novel gene therapy candidate for the treatment of Duchenne Muscular Dystrophy
Oct 11, 2021: Sarepta Therapeutics’ SRP-9001 shows sustained functiol improvements in multiple studies of patients with Duchenne
Oct 04, 2021: Solid Biosciences and Forge Biologics announce viral vector contract development and cGMP manufacturing partnership
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Alpha Anomeric, 2022
Pipeline by Astellas Gene Therapies, 2022
Pipeline by Avidity Biosciences Inc, 2022
Pipeline by Code Biotherapeutics Inc, 2022
Pipeline by Daiichi Sankyo Co Ltd, 2022
Pipeline by Dystrogen Therapeutics SA, 2022
Pipeline by Editas Medicine Inc, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Evox Therapeutics Ltd, 2022
Pipeline by FibroGenesis LLC, 2022
Pipeline by MyoGene Bio LLC, 2022
Pipeline by Myosana Therapeutics Inc, 2022
Pipeline by Nippon Shinyaku Co Ltd, 2022
Pipeline by NS Pharma Inc, 2022
Pipeline by OliPass Corporation, 2022
Pipeline by Pepgen Ltd, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by RegenxBio Inc, 2022
Pipeline by Sarepta Therapeutics Inc, 2022
Pipeline by Solid Biosciences Inc, 2022
Pipeline by Sutura Therapeutics Ltd, 2022
Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022
Pipeline by Tolerion Inc, 2022
Pipeline by Ultragenyx Pharmaceutical Inc, 2022
Pipeline by Vertex Pharmaceuticals Inc, 2022
Pipeline by Wave Life Sciences Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022